May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Increased Expression of an Inhibitor of NFkappaB, IkappaBalpha, in APCS Endows Them With the ACAID–Inducing Property
Author Affiliations & Notes
  • A.P. Ghafoori
    Harvard Medical School, Boston, MA
  • B. Turpie
    Schepens Eye Research Institute, Boston, MA
  • J.W. Streilein
    Schepens Eye Research Institute, Boston, MA
  • S. Masli
    Schepens Eye Research Institute, Boston, MA
  • Footnotes
    Commercial Relationships  A.P. Ghafoori, None; B. Turpie, None; J.W. Streilein, None; S. Masli, None.
  • Footnotes
    Support  EY013775
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1045. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.P. Ghafoori, B. Turpie, J.W. Streilein, S. Masli; Increased Expression of an Inhibitor of NFkappaB, IkappaBalpha, in APCS Endows Them With the ACAID–Inducing Property . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1045.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: ACAID–inducing APCs were found to express increased levels of IkappaBalpha which is an inhibitor of proinflammatory transcription factor NFkappaB. Up–regulated message of IkappaBalpha correlated with increased nuclear IkappaBalpha protein, in APCs exposed to TGFß2. We examined if this increased expression of this inhibitor is involved in the ACAID–promoting effects of TGFß2. Methods: Macrophage hybridoma #59 cells stably expressing anti–IkappaBalpha siRNA were pulsed with ovalbumin (OVA) and cultured in the presence of TGFß2 (5 ng/ml). The cells were examined (a) in vitro for their ability to express IkappaBalpha protein (using western blot) and their ability to secrete IL–12 in culture supernatants (using ELISA); and (b) in vivo for their capacity to suppress OVA–specific delayed hypersensitivity (DTH) when injected into naive mice immunized subsequently with OVA plus complete Freunds’ adjuvant. Similarly #59 ectopically overexpressing IkappaBalpha were tested for their ability to suppress DTH. NFkappaB activity of #59, #59 expressing siRNA and #59 overexpressing IkappaBalpha was tested by measuring nuclear levels of subunits p50 and p65 using TransAm chemiluminescence assay (Active Motif, CA). Results: APCs expressing anti– IkappaBalpha siRNA failed to express increased nuclear levels of IkappaBalpha in response to TGFß 2 treatment as against control APCs infected with an empty vector. These siRNA expressing APCs also failed to inhibit IL–12 secretion as seen in control APCs treated with TGFß 2. Also, unlike the control APCs treated with TGFß 2, anti– IkappaBalpha siRNA expressing APCs failed to suppress ova–specific DTH response in vivo . On the other hand, APCs overexpressing IkappaBalpha suppressed ova–specific DTH responses similar to TGFß2–treated APCs. Moreover, nuclear levels of NFkappaB p50 subunit were found significantly decreased after 18 hrs of TGFß2 exposure of APCs (#59). However, anti– IkappaBalpha siRNA expression in APCs prevented this decrease whereas nuclear p50 levels of IkappaBalpha overexpressing APCs were decreased as compared to their control APCs. Conclusions: TGFß2 exposure of APCs induces increased expression of IkappaBalpha which by inhibiting proinflammatory transcription factor NFkappaB prevents secretion of IL–12. This expression of IkappaBalpha in APCs is critical to their ACAID–inducing phenotype.

Keywords: ACAID • antigen presentation/processing • gene/expression 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.